SCHEMBL7848337

SCHEMBL7848337

COC(=O)COc1ccc(C(C)(C)C)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.69
LMNA P02545 3/20 0.54
MAPK1 P28482 3/20 0.54
ALDH1A1 P00352 3/20 0.54
ALOX15 P16050 1/20 0.54
APEX1 P27695 1/20 0.54
RECQL P46063 1/20 0.54
HSD17B10 Q99714 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
PTGS2 P35354 1/20 0.54
CYP2C19 P33261 3/20 0.54
POLB P06746 2/20 0.54
EPHX2 P34913 1/20 0.54
NR1H4 Q96RI1 1/20 0.54
GAA P10253 1/20 0.54
HCAR2 Q8TDS4 1/20 0.52
MAPT P10636 1/20 0.51
RAB9A P51151 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12227868 0.91 SMN1; SMN2 (0.56) SMN1; SMN2LMNAALDH1A1PTGS2CYP2C19
SCHEMBL1507666 0.89 SMN1; SMN2 (0.54) SMN1; SMN2LMNAALDH1A1PTGS2CYP2C19
SCHEMBL12227872 0.89 SMN1; SMN2 (0.54) SMN1; SMN2LMNAALDH1A1TDP1PTGS2
SCHEMBL733369 0.87 SMN1; SMN2 (0.71) SMN1; SMN2LMNAMAPK1ALDH1A1ALOX15
SCHEMBL2116437 0.87 PTGS2 (0.66) SMN1; SMN2LMNAALDH1A1HSD17B10PTGS2
SCHEMBL22059478 0.85 EPHX2 (0.79) LMNACYP2C19EPHX2NR1H4RAB9A
SCHEMBL586420 0.84 ALDH1A1 (0.64) SMN1; SMN2ALDH1A1PTGS2CYP2C19MAPT
SCHEMBL5274392 0.84 SMN1; SMN2 (0.67) SMN1; SMN2LMNAMAPK1ALDH1A1CYP2C19
SCHEMBL15426838 0.83 MEN1 (0.53) SMN1; SMN2LMNAMAPK1ALDH1A1PTGS2
SCHEMBL17364456 0.83 PTGS2 (0.49) SMN1; SMN2LMNAALDH1A1PTGS2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117897440-A Method for screening solvent for extraction of polyvinyl chloride, method for recycling waste material, recycled polyvinyl chloride and composition 株式会社LG化学 2024-04-16 CN claimed
CN-117897439-A Method for screening solvent for extraction of polyvinyl chloride, method for recovering waste material, and recovered polyvinyl chloride and composition 株式会社LG化学 2024-04-16 CN disclosed
CN-117897440-A Method for screening solvent for extraction of polyvinyl chloride, method for recycling waste material, recycled polyvinyl chloride and composition 株式会社LG化学 2024-04-16 CN disclosed
US-9365523-B2 Imidazolyl amide compounds and uses related thereto EMORY UNIVERSITY (US) 2016-06-14 US disclosed
US-20140080828-A1 IMIDAZOLYL AMIDE COMPOUNDS AND USES RELATED THERETO CHILDREN'S HEATLHCARE OF ATLANTA, INC. (US) 2014-03-20 US disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 US disclosed
US-7858616-B2 Indolinone derivatives substituted in the 6 position, their preparation and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-12-28 US disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 US disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 US disclosed
US-20090203676-A1 G-protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2009-08-13 US disclosed
US-7547703-B2 Indoline derivatives substituted in the 6-position, their preparation and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-06-16 US disclosed
US-7547703-B2 Indoline derivatives substituted in the 6-position, their preparation and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-06-16 US disclosed
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-7226906-B2 Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases ARRAY BIOPHARMA, INC. (US) 2007-06-05 US disclosed
US-7226906-B2 Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases ARRAY BIOPHARMA, INC. (US) 2007-06-05 US disclosed
US-7169936-B2 Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-30 US disclosed
US-7169936-B2 Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-30 US disclosed
US-20070004757-A1 INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS ROTH GERALD J 2007-01-04 US disclosed
US-20070004757-A1 INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS ROTH GERALD J 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140080828-A1 IMIDAZOLYL AMIDE COMPOUNDS AND USES RELATED THERETO TPMT, PNP, MTAP SMN1; SMN2 2371/4885LMNA 3734/4885MAPK1 3278/4885
US-20070004757-A1 INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS KDR, FLT1, EGFR SMN1; SMN2 4443/4885LMNA 2104/4885MAPK1 552/4885
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK SMN1; SMN2 2568/4885LMNA 4328/4885MAPK1 825/4885
US-20090203676-A1 G-protein Coupled Receptor Agonists GPR119, GCGR, GPBAR1 SMN1; SMN2 3393/4885LMNA 4434/4885MAPK1 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.